What Happened
The Department of Health and Human Services has issued a draft enforcement discretion policy stating that it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptides — BPC-157, TB-500, epitalon, KPV, MOTS-c and semax — provided they meet ten conditions.
The notice, signed by HHS Secretary Robert F. Kennedy Jr., is scheduled for Federal Register publication on October 30 under Docket No. HHS-OASH-2026-0496. It is a draft, not binding on HHS or the public, not an approval. None of the six is FDA-approved, none is on the section 503A bulk drug substances list, and FDA has not proposed adding them. Compounded drugs are not reviewed for safety, effectiveness, or quality.
Bulk substances must come from an FDA-registered original manufacturer working under current good manufacturing practice, with a certificate of analysis covering identity, purity, potency and contaminants such as endotoxins and heavy metals. Compounders must report serious adverse events and quality problems to MedWatch and to the states. Each product may contain only one active ingredient, must be labeled compounded and not for resale, and requires a patient-specific prescription. Copackaged devices must use 510(k)-cleared syringes, and oral products must document adequate bioavailability.
Who Is Affected
- Compounding pharmacies and prescribing clinicians get a written basis to operate openly; state law and liability are unchanged.
- Cash-pay patients and telehealth wellness clinics: compounded drugs generally fall outside pharmacy benefit coverage, so cost stays out of pocket.
- Gray-market vendors lose part of their pitch. HHS says the policy is meant to steer patients from research-use-only peptides sold by foreign manufacturers toward "a more controlled alternative."
- Payers inherit quality questions they have no standard to audit against.
Timeline
- July 23, 2026 — FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157, KPV and TB-500 for the 503A bulks list, ultimately backing six of seven reviewed peptides and overriding career FDA scientists who opposed all seven.
- October 14, 2026 — an interim peptide compounding access policy went to the Office of Management and Budget for review.
- October 28 — HHS announced the enforcement discretion policy.
- October 30 — Federal Register publication, with written comments due two weeks later.
- 12 to 24 months — the typical span of formal notice-and-comment rulemaking before any final FDA rule.
What This Means for Researchers
The evidence base did not move. FDA briefing materials described the available studies, including five of BPC-157, as short, small and insufficient to establish safety or effectiveness. Appendix B acknowledges that FDA's drug center recommended against listing each of the six; HHS calls several of those concerns inferential or mechanistic rather than observed, and for KPV a reflection of missing information. The practical shift is narrower than it sounds: the question facing a clinic moves from "is this lawful" to "can the compounder document what is in the vial."
How to Verify Your Peptides
Enforcement discretion certifies nothing about purity. Ask for the certificate of analysis. Our guides cover how testing works, identity, purity and fill-weight checks, and HPLC versus LC-MS methods.
Safe Alternatives
Reference pages for BPC-157 and TB-500 summarize what human data do and do not show. Vendor records track which suppliers publish independent testing, and the peptide index lists compounds with stronger clinical footing.
Sources
Regulatory announcements: HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Docket HHS-OASH-2026-0496, FR Doc 2026-22192); FDA Pharmacy Compounding Advisory Committee vote, July 2026. Industry reports on compounding quality standards.